Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496822 | 0.89 | ABCG2 (0.46) | PDE2AABCG2KMT2AMEN1KDM4E | |
| SCHEMBL496633 | 0.88 | PDE2A (0.51) | PDE2ATOP2AABCG2MAPTKMT2A | |
| SCHEMBL496651 | 0.87 | PDE2A (0.46) | PDE2ATOP2AABCG2MAPTKMT2A | |
| SCHEMBL496593 | 0.85 | PDE2A (0.46) | PDE2ATOP2AABCG2MAPTMAPK1 | |
| SCHEMBL496809 | 0.85 | PDE2A (0.46) | PDE2ATOP2AABCG2MAPTKMT2A | |
| SCHEMBL496524 | 0.85 | PDE2A (0.53) | PDE2AMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL496641 | 0.81 | MEN1 (0.44) | PDE2ATOP2AABCG2MAPTKMT2A | |
| SCHEMBL12971505 | 0.79 | TOP2A (0.36) | PDE2ATOP2AMAPTKMT2AMEN1 | |
| SCHEMBL496652 | 0.78 | ABCG2 (0.47) | PDE2AABCG2MAPTKMT2AKDM4E | |
| SCHEMBL496563 | 0.78 | PDE2A (0.46) | PDE2AMAPTKMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836207-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | disclosed |
| US-8106047-B2 | (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors; septic shock or vascular edema; neoangiogenesis or inflammatory disease | NYCOMED GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-7851472-B2 | Triazolophthalazines | NYCOMED GMBH (DE) | 2010-12-14 | — | — | US | disclosed |
| US-20100286140-A1 | TRIAZOLOPHTHALAZINES | NYCOMED GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-1791543-B1 | TRIAZOLOPHTHALAZINES | NYCOMED GMBH (DE) | 2010-06-16 | — | — | EP | disclosed |
| US-20090005372-A1 | Triazolophthalazines | ALTANA PHARMA AG (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20080312225-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| EP-1836207-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | Nycomed GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1791543-A2 | TRIAZOLOPHTHALAZINES | Altana Pharma AG (DE) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006072615-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006024640-A2 | TRIAZOLOPHTHALAZINES | ALTANA PHARMA AG (DE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286140-A1 | TRIAZOLOPHTHALAZINES | PDE2A, PDE12, PDE3A | PDE2A 1/4885TOP2A 61/4885ABCG2 1937/4885 |
| US-20090005372-A1 | Triazolophthalazines | PDE2A, PDE12, PDE3A | PDE2A 1/4885TOP2A 61/4885ABCG2 1937/4885 |
| US-20080312225-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | PDE2A 1/4885TOP2A 63/4885ABCG2 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.